September 1, 2021 | Jen Temple, Head of Communications | Reading Time: < 1 minute
Personalized cancer treatment via targeted therapies is two-to-three times more effective than standard chemotherapy for patients with advanced or metastatic cancer. But for patients to benefit, they must have access to robust biomarker testing capabilities, a challenge in many community cancer settings. Yet this testing is time-consuming and costly to outsource.
The solution? Canexia Health can help your lab deploy cancer genomics assays at a fraction of the cost of outsourcing multigene panels to a centralized lab, and without the need to invest in a costly bioinformatics infrastructure.
Our Clinical Services team supports labs with bringing precision oncology programs in-house, including the implementation and maintenance of clinical next-generation sequencing-based profiling.
Watch our video to learn how we can help you deliver on your mandate for providing best-in-class cancer care.
June 5, 2023
To discuss the development of the Endometrial ProMisE Molecular Classifier, and the new NSMP study further, we are delighted to have Dr. Jessica McAlpine and Dr. Amy Jamieson, esteemed gynecological cancer surgeons at Vancouver General Hospital, who have been instrumental in the development and implementation of this innovative tool.
May 15, 2023
We were grateful for the opportunity to attend and present at the AACR Annual Meeting last week, where three of our scientists highlighted some of the exciting work happening in our Vancouver lab.
March 28, 2023
Imagia Canexia Health announced that three abstracts highlighting the company’s new learnings and tools will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19, 2023, at the Orange County Convention Center in Orlando, Florida.